{"version":"1.0","type":"link","title":"Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer.","author_name":"Yiu DC 외","author_url":"https://prs-insight.online/author/Yiu%20DC","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/110765","thumbnail_width":1200,"thumbnail_height":630}